LP
JSPR icon

LMR Partners’s Jasper Therapeutics JSPR Stock Holding History

LMR Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,274
Closed -$99.2K – 1409
2024
Q3 		$99.2K Sell
5,274
-34,554
-87% -$688K ﹤0.01% 1043
2024
Q2 		$904K Sell
39,828
-4,117
-9% -$98.8K 0.01% 683
2024
Q1 		$1.29M Buy
+43,945
New +$781K 0.01% 620

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

LMR Partners's JSPR Position: Q4 2024 in Review

LMR Partners sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 5,274 shares — an estimated $99.2K sold.

LMR Partners first reported a position in JSPR in Q1 2024 and held it in 3 quarters. The position peaked at $1.29M in Q1 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

  • LMR Partners reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
  • LMR Partners sold 5,274 Jasper Therapeutics shares in Q4 2024, an estimated $99.2K.
  • LMR Partners first reported a position in Jasper Therapeutics in Q1 2024 and held it in 3 quarters.
  • LMR Partners's Jasper Therapeutics position peaked at $1.29M in Q1 2024.
  • 87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.